- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03865693
Effects of Pain Scrambler Therapy for the Alterations of Cerebral Blood
June 18, 2019 updated by: Hangang Sacred Heart Hospital
Effects of Pain Scrambler Therapy for the Alterations of Cerebral Blood Volume in Pain Network of Neuropathic Pain on Burn Patients
Prevalence of chronic pain has been shown to be high after thermal injury.
Post-burn neuropathic pain causes chronic disabilities that is often difficult to treat effectively.
Pain Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
To study changes in the pain network associated with neuropathic pain, magnetic resonance imaging(MRI) was used to evaluate cerebral blood volume(CBV) in patients who had been injuried by burn.
Participants (N=40, experimental 20 and control group 20) comprised patients with neuropathic pain after thermal injury.
The subjects complained of severe neuropathic pain that was rated at least 5 on the visual analogue scale (VAS), despite treatments with gabapentin medication and other physical modalities.
Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days.
The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
The intensity of neuropathic pain was measured using the visual analogue scale(VAS).
Depressive mood was assessed using the Beck Depression Scale.
Voxel-wise comparisons of relative CBV maps were made between before scrambler therapy and after 10 scrambler therapy sessions over the entire brain volume.
The relationship between individual participant CBV(measured in voxels), BDS and VAS score was also examined.
We observed decreased in the cerebral pain network of patients with burn injury.
Scrambler therapy is a non-invasive, non-medicinal modality that significantly reduced burn-associated neuropathic pain.
Scrambler therapy should be considered as a treatment option for burn survivors with severe neuropathic pain.
Study Overview
Detailed Description
The groups (scrambler therapy and sham therapy) were randomly assigned.
All subjects were recruited in scrambler thrapy and sham stimulation.
Main study outcomes included group differences in CBV changed and the the relationship between CBV changes and neuropathic pain intensity.
These analyses were performed using the same framework of the general linear model, which was repeatedly applied to each voxel with the same coordinates.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Yeong-deungpo-Dong
-
Seoul, Yeong-deungpo-Dong, Korea, Republic of, 150-719
- Recruiting
- Hangang Sacred Heart Hospital
-
Principal Investigator:
- So Young Joo, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Burn patients
- severe neuropatic pain rated at least 5 on the 10-point numerical rating scale (NRS)
Exclusion Criteria:
- cardiac arrest history
- history of neurologi disease or brain surgery
- unstable heart disease or presence of a cardiac pacemaker
- pain resulting from other causes like as neuromuscular diseases
- psychiatric disorder
- diabetes mellitus
- abnormal renal function
- contraindication for MRI, or pregnancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: scarmbler treatment group
Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days.
The experimental participants were received scarmbler therapy 10 times for 2 weeks.
The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
|
Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
|
Sham Comparator: sham treatment group
conservative management without scarmbler therapy
|
Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
neuropathic pain score
Time Frame: after 4 weeks scrambler therapy
|
visual analog scale, Zero ("0") represented no pain and 10 represented unbearable symptoms
|
after 4 weeks scrambler therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cerebral blood volume
Time Frame: after 4 weeks scrambler therapy
|
Cerebral blood volume(CBV) is a hemodynamic variable that is highly correlated with oxygen metabolism, representing the fraction of cerebral tissue volume occupied by blood at a given time point.
|
after 4 weeks scrambler therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Cheong Hoon Seo, M.D., Hangang Sacred Heart Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Joo SY, Cho YS, Cho SR, Kym D, Seo CH. Effects of pain Scrambler therapy for management of burn scar pruritus: A pilot study. Burns. 2017 May;43(3):514-519. doi: 10.1016/j.burns.2016.09.028. Epub 2016 Oct 15.
- Majithia N, Smith TJ, Coyne PJ, Abdi S, Pachman DR, Lachance D, Shelerud R, Cheville A, Basford JR, Farley D, O'Neill C, Ruddy KJ, Sparadeo F, Beutler A, Loprinzi CL. Scrambler Therapy for the management of chronic pain. Support Care Cancer. 2016 Jun;24(6):2807-14. doi: 10.1007/s00520-016-3177-3. Epub 2016 Apr 4.
- Lee SY, Park CH, Cho YS, Kim L, Yoo JW, Joo SY, Seo CH. Scrambler Therapy for Chronic Pain after Burns and Its Effect on the Cerebral Pain Network: A Prospective, Double-Blinded, Randomized Controlled Trial. J Clin Med. 2022 Jul 22;11(15):4255. doi: 10.3390/jcm11154255.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
July 1, 2019
Primary Completion (Anticipated)
August 31, 2020
Study Completion (Anticipated)
November 30, 2020
Study Registration Dates
First Submitted
March 5, 2019
First Submitted That Met QC Criteria
March 5, 2019
First Posted (Actual)
March 7, 2019
Study Record Updates
Last Update Posted (Actual)
June 20, 2019
Last Update Submitted That Met QC Criteria
June 18, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HangangSHH-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
after review
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain, Neuropathic
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
-
Ashwin ViswanathanBoston Scientific CorporationNot yet recruitingChronic Pain | Neuropathic Pain | Pain, NeuropathicUnited States
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
Clinical Trials on scarmbler therapy
-
University of Alabama at BirminghamCompleted
-
Mennallah Ahmed Mohamed Anwar ElgendyNot yet recruiting
-
Spaulding Rehabilitation HospitalActive, not recruiting
-
Istanbul Medipol University HospitalCompleted
-
St. Jude Children's Research HospitalCompletedStem Cell Transplant | Bone MarrowUnited States, Canada
-
Universidad de ZaragozaCompletedPlagiocephaly | Plagiocephaly, Nonsynostotic | Plagiocephaly, PositionalSpain
-
National Taiwan University HospitalNot yet recruitingAutism | Language Delay | Speech Disorders in Children
-
Riphah International UniversityCompleted
-
Hospital for Special Surgery, New YorkActive, not recruiting